Italia - italiensk - Ministero della Salute

teva italia srl -

Den europeiske union - italiensk - EMA (European Medicines Agency)

viiv healthcare bv - dolutegravir - infezioni da hiv - antivirali per uso sistemico - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg. tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.

Den europeiske union - italiensk - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - infezioni acquisite in comunità - antibatterici per uso sistemico, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 e 5. dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antibatterici..

Den europeiske union - italiensk - EMA (European Medicines Agency)

gilead sciences ireland uc - elvitegravir, cobicistat, emtricitabina, tenofovir disoproxil fumarato - infezioni da hiv - antivirals for treatment of hiv infections, combinations, antivirals for systemic use - trattamento del virus dell'immunodeficienza umana 1 (hiv-1) infezione in adulti età compresa tra 18 anni e oltre che sono naïve al trattamento antiretrovirale o sono infettate con hiv 1 senza mutazioni note associate a resistenza ad uno qualsiasi dei tre agenti antiretrovirali in stribild.

Den europeiske union - italiensk - EMA (European Medicines Agency)

pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - agenti antineoplastici - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Den europeiske union - italiensk - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - agenti antineoplastici - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Den europeiske union - italiensk - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - disodio emipentaidrato di pemetrexed - carcinoma, non-small-cell lung; mesothelioma - agenti antineoplastici - malignant pleural mesothelioma ciambra in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer ciambra in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. ciambra è indicato come monoterapia per il trattamento di mantenimento del carcinoma localmente avanzato o metastatico non a piccole cellule del cancro del polmone diversa prevalentemente istologia a cellule squamose in pazienti la cui malattia non ha progredito immediatamente dopo chemioterapia a base di platino. ciambra è indicato come monoterapia per il trattamento di seconda linea di pazienti con carcinoma localmente avanzato o metastatico non a piccole cellule del cancro del polmone diversa prevalentemente istologia a cellule squamose.

Italia - italiensk - Ministero della Salute

erba vita spa -

Italia - italiensk - Ministero della Salute

erba vita spa -

Italia - italiensk - Ministero della Salute

arkofarm srl -